

## Submission

Home > Submission

You can use the options below to view your submission. Where appropriate you can also add to and update your submission and send the details for approval.

Submission Details	
Status	Accepted
Open Date	01/04/2016
Deadline Date	29/04/2016
Date Submitted	28/04/2016
Type	Performance In Delivery
NHS provider	Maldstone and Tunbridge Wells NHS Trust

Showing records 1 to 11 of 11.  
Pages: 1

Id	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Maximum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Target Date To Recruit Patients Agreed?	Recruitment		Total Number Of Participants Recruited	Reason For Closure Of Trial	Comments	
								Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date				
7975	15/WM/0457	195511	DARATUMUMAB: An Open-Label Treatment Use Protocol for Daratumumab in Subjects with Multiple Myeloma Who Have Received at Least 3 Prior Lines of Therapy (Including a Proteasome Inhibitor and an Immunomodulatory Agent) or are Double Refractory to a Pr	Number Agreed	5	5	Not Available / Not Agreed	0	0	0	Recruitment Finished		
7976	15/LO/1807	187302	Checkmate 331 An Open-Label, Randomized, Phase 3 study of Nivolumab or chemotherapy in subjects with resectable small-cell lung cancer after Platinum-Based first line chemotherapy. CA209-331	Number Agreed	7	7	Not Available / Not Agreed	0	0	0	Recruitment Finished		
7977	13/EM/0348	122371	Monoprost compared with Lumigan In POA glaucoma/Ocular hypertension	Number Agreed	6	6	Date Agreed	30/04/2016	0	0	Recruitment Finished		
7978	14/NW/1258	161891	ARAMIS 3104007 ORION - A multicentre, randomised, double-blind, placebo-controlled, phase 111 efficacy and safety study of ODM-201 in men with high risk non-metastatic castration-resistant prostate cancer.	Number Agreed	4	4	Not Available / Not Agreed	0	0	0	Recruitment Finished		
7979	14/WM/1055	152229	AB12006 - A prospective, multicentre, randomized, double blind, placebo-controlled, 2-parallel group, phase 3 study to compare the efficacy and safety of masitinib in combination with FOLFIRI (irinotecan, 5-fluorouracil and folinic acid) to placebo 1	Number Agreed	6	6	Date Agreed	01/03/2016	1	0	01/03/2016	Recruitment Finished	
7980	15/EM/0344	183906	MORAB-009-201 A randomised, double-blind, place-controlled study of the safety and efficacy of amatumumab in combination with pemetrexed and cisplatin in subjects with unresectable malignant pleural mesothelioma	Number Agreed	3	3	Not Available / Not Agreed		0	0	Recruitment Finished		
7981	15/LO/0016	164539	MONARCH 3: A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Study of Nonscriptional Aromatase Inhibitors (Anastrozole or Letrozole) Plus LY2395219, a CDK4/6 Inhibitor, or Placebo in Postmenopausal Women with Hormone Receptor-Positive, HER2-Negative	Number Agreed	3	3	Date Agreed	30/11/2015	0	0	30/11/2015	Recruitment Finished	
7982	15/LO/0940	179018	Victoria: GS-US-312-0118 A phase 3 randomised open-label study evaluating the efficacy and safety of idelalisib in combination with obinutuzumab compared to chlorambucil in combination with obinutuzumab for previously untreated chronic lymphocytic l	Number Agreed	4	4	Not Available / Not Agreed		0	0	Recruitment Finished		
7983	13/LO/1557	135995	CALM-NET: A Phase 4, Multicentre, Open Label, Single Group Exploratory Study to Assess the Clinical Value of Enumeration of Circulating Tumour Cells (CTCs) to Predict Clinical Symptomatic Response and Progression Free Survival in Patients receiving D	Number Agreed	2	2	Date Agreed	30/11/2015	0	0	30/11/2015	Recruitment Finished	
7984	15/LO/0691	174324	CHECKMATE 171: BMS-936558 A Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Systemic Regimen	Number Agreed	36	36	Not Available / Not Agreed		0	0	Recruitment Finished		

Format dd/mm/yyyy. Please show the date agreed to recruit patients. Leave blank if unavailable.